The main focus of this use case workpackage is on existing data from DFG clinical research group KFO179, data from the BMBF-MetastaSys-consortium as well as the BMBF consortia BreastSys, Her2Low and MMML-Demonstrators. Consequently, we have acquired resources such as interesting (and quality controlled) data from patient care, the cancer registry (using the Onkostar), and data from clinical trials (using the Secutrial and OpenClinica). We have already demonstrated the feasibility of context specific pathways in two example projects in the developmental phase (WP6). Currently we started to analyze tissue from patients suffering from CRC with limited hepatic or surgeryrequiring brain metastases. Metastatic tissue was collected freshly and analyzed by RNA-Seq and Reverse Phase Protein Arrays (RPPA) within the BMBF-funded consortium MetastaSys as well as HER2LOW. Molecular subtyping of the metastases and correlation with clinical-pathological data and oncological long-term course of the patients were performed based on the expression data. Together with the methodology work-package WP1-WP5 and the clinicians in WP6 we will systematically apply the newly developed tools on this multilayer expression data from colorectal cancer as well as breast cancer patients to identify affected pathways and master regulators, which but could be useful as a prognostic marker and facilitate colorectal cancer therapy stratification in the future. Finally, the identified targets will be validated against the retrospectively collected clinical information with WP6 (Application in oncology).